JPRN-UMIN000013206已完成未知
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer - Gemcitabine plus nab-paclitaxel treatment for pancreas cancer
Yokohama City University Hospital Oncology0 个研究点目标入组 0 人开始时间: 2014年2月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •other malignant diseases Paformance status 3,4 uncontrolable pleural effusion and/or ascites uncontrolable infection uncontrolable DM past treatment history to pancreas cancer
研究者
相似试验
招募中
1 期
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615)pancreatic cancerJPRN-jRCTs061180074FUKUBA Nobuhiko35
招募中
1 期
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II studyunresected/recurrent metastatic pancreatic cancerJPRN-UMIN000035158Shimane University Hospital31
已完成
不适用
Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasisThe patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.JPRN-UMIN000018878Study group of pancreatic cancer with peritoneal metastasis48
招募中
不适用
Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomypancreatic cancerJPRN-UMIN000031203niversity of Yamanashi30
已完成
2 期
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24